Drug Trial Radar · NCT07115004
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 15, 2025
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Vega Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Conditions
- Von Willebrand Disease (VWD)
Interventions
VGA039Drug
VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of bleeding events [Efficacy]Time frame: Time Frame: From 7 days after informed consent until 49 weeks after SC study drug initiation
Locations
32 sites in 10 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Luskin Orthopaedic Institute For Children
Los Angeles, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
UC Davis Medical Center
Sacramento, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
University of Michigan Health
Ann Arbor, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Science 37, Inc. (Virtual Clinical MetaSite)
Morrisville, North Carolina · Recruiting
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania · Recruiting
UT Southwestern Children's Hospital
Dallas, Texas · Recruiting
Washington Center for Bleeding Disorders
Seattle, Washington · Recruiting
Royal Prince Alfred Hospital, Institute of Haematology
Sydney, New South Wales (nsw), Australia · Recruiting
Royal Brisbane & Women's Hospital (RBWH), Queensland Haemophilia Centre
Brisbane, Queensland, Australia · Recruiting
The Alfred Hospital (Alfred Health),Monash University
Melbourne, Victoria, Australia · Recruiting
Medical University of Vienna
Vienna, Austria · Recruiting
Multihemo - Oncoclínicas
Recife, Pernambuco, Brazil · Recruiting
Centro de Hemoterapia e Hematologia do Rio de Janeiro (HEMORIO)
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
emocentro UNICAMP (Centro de Hematologia e Hemoterapia da UNICAMP), University of Campinas (UNICAMP)
Campinas, São Paulo, Brazil · Recruiting
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
São Paulo, São Paulo, Brazil · Recruiting
K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი)
Tbilisi, Georgia · Recruiting
Vivantes Klinikum im Friedrichshain
Berlin, Germany · Recruiting
Frankfurt University Hospital (Universitätsmedizin Frankfurt)
Frankfurt, Germany · Recruiting
St. James's Hospital, National Coagulation Centre
Dublin, Dublin, Ireland · Recruiting
Azienda Ospedaliero-Universitaria Careggi (Careggi University Hospital)
Florence, Italy · Recruiting
University of Milan
Milan, Milan, Italy · Recruiting
Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist
Johannesburg, South Africa · Recruiting
Worthwhile Clinical Trials Lakeview Hospital
Benoni, Gauteng, South Africa · Recruiting
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, Greater London, United Kingdom · Recruiting
Royal Free London NHS Foundation Trust,
London, London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.